checkAd

     241  0 Kommentare OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares - Seite 2

    Enquiries:

    OKYO Pharma Limited Gary S. Jacob, Chief Executive Officer +44 (0)20 7495 2379
         
    Investor Relations Paul Spencer +44 (0)20 7495 2379

    Lesen Sie auch


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 2 von 2

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares - Seite 2 LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) - OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today announced …